DSS amends $12.86M promissory note with Impact BioMedical, extends maturity to 2030

DSS, INC.

Principal balance funded to $12,859,328.60, including $1,231,483.14 interest funding advanced Jan 17, 2024.
Maturity extended to September 30, 2030; interest-only payments through Jan 2026, then monthly $126,380.80.
Interest rate set at WSJ Prime + 0.50% (initial 9.00%); secured by blanket first lien on all Impact assets including patents.
DSS is the lender and majority shareholder of Impact BioMedical, indicating continued related-party support.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DSS, INC. amended Amendment with Impact BioMedical, Inc. valued at $859,328.60 (effective 2024-01-18).

Action: amendment
Agreement: credit facility
Counterparty: Impact BioMedical, Inc.
Value: $859,328.60
Effective: 2024-01-18

Exact text from the filing

Effective January 18, 2024, DSS, Inc. (the “Company”) and Impact BioMedical, Inc., a Nevada corporation (“Impact”) entered into an amendment to the revolving promissory note dated March 1, 2023

View on SEC.gov

Browse all material agreements →

DSS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-003268

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.